Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.

myTempleHealth
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

view all Clinical Trials

Overview

Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD.

Clinical Trial Information

Protocol

TIRB# 30801

Phase

3

Condition(s)

Chronic Obstructive Pulmonary Disease (COPD)

Investigator

Gerard Criner, MD

Coordinator

Debasree Sana Boral

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Related Clinical Trials

Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation

TIRB# 29791
  • Conditions: Chronic Obstructive Pulmonary Disease (COPD)
  • Investigator: Gerard Criner, MD
  • Coordinator: David Miller
View Details

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)

TIRB# 24733
  • Conditions: Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis (Including IPF), Interstitial Lung Disease (ILD)
  • Investigator: Gerard Criner, MD
  • Coordinator: David Miller
View Details

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

TIRB# 31322
  • Conditions: Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis (Including IPF), Interstitial Lung Disease (ILD)
  • Investigator: Gerard Criner, MD
  • Coordinator: Debasree Sana Boral
View Details